Related references
Note: Only part of the references are listed.Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study
E. Y. Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase II trial of lapatinib in hormone refractory prostate cancer
Y. E. Whang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)
J. S. De Bono et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
Derek S. Welsbie et al.
CANCER RESEARCH (2009)
Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway
Begona Mellado et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Emerging therapies in castrate-resistant prostate cancer
Kiran Lassi et al.
CURRENT OPINION IN ONCOLOGY (2009)
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
Kamilla Malinowska et al.
ENDOCRINE-RELATED CANCER (2009)
A Novel Androgen Receptor Amino Terminal Region Reveals Two Classes of Amino/Carboxyl Interaction-Deficient Variants with Divergent Capacity to Activate Responsive Sites in Chromatin
Eleanor F. Need et al.
ENDOCRINOLOGY (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity
G. Attard et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation Therapy
Satyan K. Shah et al.
JOURNAL OF UROLOGY (2009)
Inhibition of Androgen Receptor Transcriptional Activity as a Novel Mechanism of Action of Arsenic
Adena E. Rosenblatt et al.
MOLECULAR ENDOCRINOLOGY (2009)
Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer
S. J. Freedland et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
Jennifer A. Locke et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer
Rohit Mehra et al.
CANCER RESEARCH (2008)
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation
Angela Seaton et al.
CARCINOGENESIS (2008)
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis
Outi R. Saramaki et al.
CLINICAL CANCER RESEARCH (2008)
Wnt Signaling and Prostate Cancer
Daniel Robinson et al.
CURRENT DRUG TARGETS (2008)
Androgen deprivation therapy for prostate cancer
Eric A. Singer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer
Mari Bjorkman et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Prostate cancer stem cells: A new target for therapy
Norman J. Maitland et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of the TMPRSS2-ERG gene fusion in prostate cancer
Arul M. Chinnaiyan
NEOPLASIA (2008)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G. Attard et al.
ONCOGENE (2008)
Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex
Hannelore V. Heemers et al.
ENDOCRINE REVIEWS (2007)
Androgen receptor structural and functional elements: Role and regulation in prostate cancer
Scott M. Dehm et al.
MOLECULAR ENDOCRINOLOGY (2007)
ARA54 is involved in transcriptional regulation of the cyclin D1 gene in human cancer cells
Hirotoshi Kikuchi et al.
CARCINOGENESIS (2007)
Treating prostate cancer: A rationale for targeting local oestrogens
Stuart J. Ellem et al.
NATURE REVIEWS CANCER (2007)
The lethal phenotype of cancer: The molecular basis of death due to malignancy
Robert D. Loberg et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
F. Demichelis et al.
ONCOGENE (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
Elahe A. Mostaghel et al.
CANCER RESEARCH (2007)
Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo
Guangyu Gu et al.
CANCER RESEARCH (2007)
Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level
Chi-Ming Chiu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: Studies on the possible mechanism of action in DU145 cells
A. Pravettoni et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2007)
Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/akt pathway in prostate cancer
Yu Wang et al.
CURRENT CANCER DRUG TARGETS (2007)
Drug Insight: role of the androgen receptor in the development and progression of prostate cancer
Mary-Ellen Taplin
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
The case for secondary hormonal therapies in the chemotherapy age
Eric J. Small et al.
JOURNAL OF UROLOGY (2006)
Persistent intraprostatic androgen concentrations after medical castration in healthy men
Stephanie T. Page et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
TMPRSS2:: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
Sven Perner et al.
CANCER RESEARCH (2006)
Prospective identification of tumorigenic prostate cancer stem cells
AT Collins et al.
CANCER RESEARCH (2005)
Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
HI Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma
H Lee et al.
CANCER (2005)
Expression of androgen receptor coactivator ARA70/ELE1 in androgenic alopecia
P Lee et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2005)
Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer
MR Freeman et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2005)
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Z Culig et al.
ENDOCRINE-RELATED CANCER (2005)
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
LC Wu et al.
CANCER RESEARCH (2005)
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases
WD Figg et al.
JOURNAL OF UROLOGY (2005)
Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells
S Baron et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
Structural and functional consequences of glutamine tract variation in the androgen receptor
G Buchanan et al.
HUMAN MOLECULAR GENETICS (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action
MA Eisenberger et al.
UROLOGY (2004)
Adrenal androgens and intracrinology
F Labrie
SEMINARS IN REPRODUCTIVE MEDICINE (2004)
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor
ZG Kang et al.
MOLECULAR ENDOCRINOLOGY (2004)
EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR)
L Bonaccorsi et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential
VJ Assikis et al.
CLINICAL CANCER RESEARCH (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Hsp90 as a therapeutic target in prostate cancer
DB Solit et al.
SEMINARS IN ONCOLOGY (2003)
Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines
C Mestayer et al.
PROSTATE (2003)
National practice patterns and time trends in androgen ablation for localized prostate cancer
MR Cooperberg et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Histone deacetylase inhibitors: from target to clinical trials
WK Kelly et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer
P Li et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer
MV Meng et al.
UROLOGY (2002)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Molecular biology of the androgen receptor: From molecular understanding to the clinic
IE Eder et al.
EUROPEAN UROLOGY (2001)
CREB-binding protein and p300 in transcriptional regulation
N Vo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation
A Migliaccio et al.
EMBO JOURNAL (2000)
Clinical states in prostate cancer: Toward a dynamic model of disease progression
HI Scher et al.
UROLOGY (2000)
Share Paper
